![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Meta-Analysis of the Real-World Effectiveness of Ombitasvir/Paritaprevir ritonavir ± Dasabuvir ± Ribavirin in Patients With HCV Genotype 1 or 4 Infection
|
|
|
Reported by Jules Levin
EASL Paris Special Meeting - Roadmap for a Cure Sept 23-24 2016
Heiner Wedemeyer1, Antonio Craxi2, Eli Zuckerman3, Douglas Dieterich4, Robert Flisiak5, Stuart K Roberts6, Andreas Pangerl7, Zhenzhen Zhang7, Marisol Martinez7, Yanjun Bao7, Jose-Luis Calleja8 1Medizinische Hochschule Hannover, Hannover, Germany; 2AOU Policlinico "P Giaccone" Dip Di Gastroenterologia ed Epatologia DBMIS, Palermo, Italy; 3Carmel Medical Center Liver Institute, Haifa, Israel; 4Mount Sinai Hospital, New York, New York, United States; 5Klinika Chorob Zakaznych i Hepatologii UM w Bialymstoku, Bialystok, Poland; 6Alfred Hospital and Monash University, Melbourne, Victoria, Australia; 7AbbVie Inc., North Chicago, Illinois, United States; 8Hospital Universitario Puerta de Hierro, Universidad Autonoma de Madrid, Madrid, Spain
![IAC1](../images/092616/092616-9/IAC1.gif)
![IAC2](../images/092616/092616-9/IAC2.gif)
![IAC3](../images/092616/092616-9/IAC3.gif)
![IAC4](../images/092616/092616-9/IAC4.gif)
![IAC5](../images/092616/092616-9/IAC5.gif)
![IAC6](../images/092616/092616-9/IAC6.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|